Top 5 Most Read RNS's on Vox Markets for Monday 5th September 2022
Episode 871, Sep 05, 2022, 06:52 AM
5. Alien Metals #UFO - Acquisition agreement boosts Hancock Development.
Has entered into a binding Heads of Agreement with Mallina Exploration to acquire a strategic tenement (currently under application with the Department of Mines, Industry Regulation and Safety DMRIS, Western Australia) bounding the Hancock Project key to the development of the Project.
(Click here to read the RNS)
4. Clontarf Energy #CLON - Share Price Movement and Shareholder Update.
They note the increase in the Clontarf share price on 2 September 2022 and can confirm that there is no new price sensitive information required to be disclosed but have provided an update on operations.
(Click here to read the RNS)
3. Synairgen #SNG Company Announce Collaboration on UNIVERSAL Trial
Synairgen announces its collaboration on the UNIVERSAL trial, an observational study of patients hospitalised due to a range of respiratory viruses
(Click here to read the RNS)
2. Supply @ME Capital #SYME Issue of Equity & Total Voting Rights.
It is to issued the fifth mandatory tranche of shares to Venus Capital S.A. ("Venus Capital"), under the key terms of the equity funding facility previously announced.
(Click here to read the RNS)
1. Avacta Group #AVCT AVA6000 receives Orphan Drug Designation from FDA.
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
(Click here to read the RNS)
Has entered into a binding Heads of Agreement with Mallina Exploration to acquire a strategic tenement (currently under application with the Department of Mines, Industry Regulation and Safety DMRIS, Western Australia) bounding the Hancock Project key to the development of the Project.
(Click here to read the RNS)
4. Clontarf Energy #CLON - Share Price Movement and Shareholder Update.
They note the increase in the Clontarf share price on 2 September 2022 and can confirm that there is no new price sensitive information required to be disclosed but have provided an update on operations.
(Click here to read the RNS)
3. Synairgen #SNG Company Announce Collaboration on UNIVERSAL Trial
Synairgen announces its collaboration on the UNIVERSAL trial, an observational study of patients hospitalised due to a range of respiratory viruses
(Click here to read the RNS)
2. Supply @ME Capital #SYME Issue of Equity & Total Voting Rights.
It is to issued the fifth mandatory tranche of shares to Venus Capital S.A. ("Venus Capital"), under the key terms of the equity funding facility previously announced.
(Click here to read the RNS)
1. Avacta Group #AVCT AVA6000 receives Orphan Drug Designation from FDA.
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.
(Click here to read the RNS)